

REMARKS

In response to the Notice of Non-Responsive Amendment mailed June 13, 2008, Applicants respectfully submit the following election and remarks.

Applicants elect the following species, in response to Examiner assertion that the new claims contain patentably distinct species:


- Myocardial ischemia (as encompassed by claims 57-63);
- Human SPHK1 (as encompassed by claims 64 and 66); and
- AF200328 (as encompassed by claims 65 and 67).

Applicants will amend the present claims to reflect the Examiner's decision regarding the traversal of the restriction requirement. Amending claim 64, for example, would be premature prior to Examiner's decision. Claim 57, and therefore dependent claims therefrom, reflects the only change made. Support for the new claims is found in the originally filed application and in the specification thereof. No new matter has been added.

In view of the foregoing, Applicants submit the application is now in condition for allowance and respectfully requests early notice to that effect. Favorable consideration of this application is respectfully requested. Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-3343


Paul J. Paglierani
Attorney for Applicants
Reg. No. 52,498

Date: July 14, 2008